Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
Crossref DOI link: https://doi.org/10.1186/s12935-015-0162-8
Published Online: 2015-02-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Genther Williams, Sybil M
Kuznicki, Apryle M
Andrade, Paula
Dolinski, Brian M
Elbi, Cem
O’Hagan, Ronan C
Toniatti, Carlo
License valid from 2015-02-04
Article History
Received: 27 November 2013
Accepted: 14 January 2015
First Online: 4 February 2015